格隆汇3月4日｜再鼎医药(ZLAB.US)盘前涨超3%，报32.7美元。消息面上，再鼎医药公布2024年度财报，总收入同比增加49.6%至3.99亿美元，主要是艾加莫德持续的强劲表现以及则乐和纽再乐销售收入持续增长。该公司预计2025年全年总收入将介于5.60亿至5.90亿美元之间，到第四季度实现非美国公认会计准则经营利润盈利。

花旗将再鼎医药美股目标价由70美元轻微上调至71美元，给予“买入”评级，相信今年的渠道数据、Vygart增长、越来越接近2026年KarXT推出的前景，应能重新激发投资者对该股的情绪。高盛将再鼎医药H股目标价从40.4港元上调至42.01港元，给予“买入”评级，重申2025年是再鼎医药发展里程碑年。中金将再鼎医药H股目标价上调22.5%至34.41港元，维持“跑赢大市”评级，留意到公司在今明两年有大量的催化剂。(格隆汇)

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.